Elutia Inc (ELUT) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Elutia Inc   (NASDAQ: ELUT)

Elutia Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Elutia Inc in the second quarter 2026?
Elutia Inc achieved a return on average equity (ROE) of 940.81 % in its second quarter 2026 a new company high.

While the company's net income was fading, Elutia Inc was able to improve its ROE compared to the first quarter 2026.

Within the Biotechnology & Pharmaceuticals industry Elutia Inc achieved the highest return on equity. While the total ranking for ROE unchanged, relative to the first quarter 2026 at no. .

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions 52 50 53 -26 -21
Return On Equity (TTM) 940.81 % - - - -
ELUT's Total Ranking # # # # #
Equity (TTM) in Millions 16 23 28 -44 -42
Seq. Equity Change -30.1 % -18.59 % - - -
Seq. Net Income Change - - - - -

Back to ELUT Management Effectiveness >> ELUT's 5 Years Annual ROE >> Compare ELUT ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 0
Sector # 0
Overall #

Return On Equity Statistics
High Average Low
940.81 %
-332.2 %
-1819.23 %
(Jun 30 2026)   (Sep 30 2022)





ELUT Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 28 -46 -39 -5 14
Y / Y Equity Change - - - - -35.09 %
Net Income in Millions 53 -54 -38 -33 -25
Y / Y Net Income Change - - - - -
Return On Equity 192.9 % - - - -183.66 %

Back to ELUT Management Effectiveness >> ELUT's 5 Years Annual ROE >> Compare ELUT ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 192.9 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ELUT's' Return on Equity at Yahoo Finance
ELUT's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ELUT's Competitors
Subscribers only: Roe for Elutia Inc 's Suppliers
Subscribers only: Return On Equity for ELUT's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Glucotrack Inc   1,114.03 %
Elutia Inc   940.81 %
Meiragtx Holdings Plc  283.67 %
Silexion Therapeutics Corp  276.59 %
Actinium Pharmaceuticals Inc  213.46 %

Date modified: 2026-09-08T17:33:17+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.